PF-9363 (C007B-386202)

PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancerIn VitroPF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker. PF-9363 leads to down regulation of a specific set of genes involved in ESR1 pathway, cell cycle and stem cell pathways. PF-9363 shows that the IC 50 values for ZR75-1 and T47D are 0.3 nM and 0.9 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: ZR75-1, T47D and MCF7 cells Concentration: 0~1 μM Incubation Time: 1 day Result: Down-regulated the expression of H3K23Ac biomarker.In VivoPF-9363 shows strong anti-tumor activity in patient-derived xenograft models . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:KAT6A/KAT6B. Specification: 0.99 Molecular Formula: C20H20N4O6S Molecular Weight: 444.46 PubChem CID: 155411202

UPC:

12352200

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

P650291-10mg

CAS:

2569009-58-9

Product Size:

10mg